RedHill Biopharma

#RDHL’s RHB-204 comparable MAP killing efficacy to RHB-104, with lower doses. Key step in RHB-204’s FDA-guided path to potential groundbreaking MAP-related approach to #Crohns. Multiple FDA designations, possible PRV and regulatory exclusivities. $RDHL PR: bit.ly/3PcoCrV

$RDHL FY2025: Tenacity, transactions & traction - transformed #Talicia business with $4M Cumberland $CPIX deal, RHB-102 deal worth up to $60M with @Hyloris, positive equity at end 2025 & R&D advances in #Crohn’s, #oncology & #GLP1 GI effects. #RDHL PR: bit.ly/4e6x5Hj

New preclinical data presented @AACR #AACR2026 annual meeting shows positive effects of #RDHL’s #opaganib as potential add-on therapy in models of #neuroblastoma (#NB) and triple-negative #breastcancer (#TNBC). $RDHL PR: bit.ly/4vJ6IgZ

#RDHL announces the start of joint U.S. commercialization of #Talicia with Cumberland ($CPIX), with full sales and operational launch commencing to support accelerated market penetration and expanded reach. $RDHL PR: bit.ly/4aGi5wg

#RDHL progress for #RHB-102 (#Bekinda®) in multiple GI indications, including development via FDA 505(b)(2) route, as a once-daily pill for #GLP1 GI side effects – no. 1 reason patients stop therapy, limiting $billion GLP-1 market growth. $RDHL PR: bit.ly/4jJRz9L

#RDHL’s opaganib plus venetoclax halves number of venetoclax-resistant #CLL #cancer cells in vivo compared to control – potential as add-on therapy to $2.5B blockbuster in emerging venetoclax-resistant CLL therapeutic challenge. $RDHL PR: bit.ly/3L3GqDz @GamberaleRomina

$RDHL successfully regains compliance with the @Nasdaq stockholders’ equity requirement. #RDHL PR: bit.ly/4iqrfk0

$RDHL’s $10.5 million New York Supreme Court judgment win now final for enforcement. No further appeal permissible. 9% annual statutory interest continues to accrue on award. #RDHL PR: bit.ly/47WQgzC

$RDHL secures $4 million strategic investment & U.S. co-commercialization partnership with $CPIX (Cumberland) for a 30% stake in #RDHL’s #Talicia business & shared net revenues - set to accelerate sales growth & deliver significant efficiencies. PR: bit.ly/42QLkcS

#RDHL is deeply saddened by the loss of our dear friend & SAB member, Prof. Thomas Borody. He will be greatly missed, but his legacy lives on - 1st to formulate today’s gold standard triple therapy for #HPylori & paving the way for a potential game-changing #Crohnsdisease therapy

$RDHL signs new $1.8 million + royalties Middle East deal for #Talicia - speeds entry to new Middle East markets. #RDHL receives $0.5M guaranteed payments + minimum of $1.3M in near-term milestone payments, and net sales royalties. PR: bit.ly/4gWMyZG

$RDHL wins New York Supreme Court appeal, upholding $10 million summary judgment against Kukbo, unequivocally dismissing Kukbo’s defense and stating that RedHill had fulfilled all obligations. #RDHL PR: bit.ly/487tANM

$RDHL 1H25: Bayer-supported #opaganib prostate cancer & groundbreaking #RHB-204 Crohn’s studies advancing, #Talicia growth – numbers & territories, up to $60 million #RHB-102 to @Hyloris deal, net revenue up 60% & gross profit doubled. #RDHL PR: bit.ly/4845J1p

$RDHL awarded $1.8 million in legal costs and expenses by #NewYorkSupremeCourt, in addition to RedHill’s prior $8.25 million #NewYork #SupremeCourt summary judgment win. Awards include 9% ongoing statutory interest accrual. #RDHL PR: bit.ly/4mRdcoK

#RDHL has received $1.1 million in first ex-U.S. #Talicia licensing payments. $RDHL PR: bit.ly/45mZZ11

Positive #FDA feedback for #RDHL’s #RHB204 approval path for #Crohnsdisease. Groundbreaking: 1st in a MAP+ only patient group & cutting-edge MAP testing enabling smaller sample size, lower cost & faster completion; Non-dilutive funding planned. $RDHL PR: bit.ly/46h0MBD

@anzuP @Bayer @ramsay Apologies for the incorrect tag @ANZUPtrials

Recruitment initiated for unique @ANZUP led, @Bayer & @Ramsay supported, #RDHL P2 opaganib + darolutamide study in patients with advanced prostate cancer using novel precision medicine patient selection companion lipid biomarker test (PCPro ). $RDHL PR: bit.ly/44bwheX

#RDHL secures Kukbo asset freeze following $RDHL’s $8.25 million plus legal fees New York Supreme Court summary judgment win. Read the PR: bit.ly/4k0fUra